Invasive pneumococcal disease: From a tertiary care hospital in the post-vaccine era


BASARANOGLU S. T., ONCEL E. K., Aykac K., ÖZSÜREKCİ Y., CENGİZ A. B., KARA A., ...More

HUMAN VACCINES & IMMUNOTHERAPEUTICS, vol.13, no.4, pp.962-964, 2017 (SCI-Expanded) identifier identifier identifier

Abstract

A breakthrough infection occurring with 13-valent pneumococcal conjugate vaccine (PCV13) in Turkey are previously described. A breakthrough infection is defined as IPD in a child who had received 1 PCV-7 or PCV-13 and for which the pneumococcal isolate was a vaccine serotype. During one year period, among 6 patients with invasive pneumococcal infection, 2 patients were considered to have a vaccine failure with serotype 19F. Antibiotic resistance results were remarkable; macrolide resistance were observed in all strains except one, and high and intermediate penicillin resistance were determined in 2 strains.